United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in a pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in a pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Ireland - English - HPRA (Health Products Regulatory Authority)

bracco uk limited - barium sulfate - powder for rectal suspension - 94 %w/w

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bracco uk ltd - barium sulfate - powder for oral or rectal suspension - 960mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bracco uk ltd - barium sulfate - oral suspension - 49mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bracco uk ltd - barium sulfate - oral suspension - 980mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bracco uk ltd - barium sulfate - enema - 940mg/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

regional health ltd - barium sulfate equivalent to 56% w/w.barium sulphate 99.0% w/v-101% w/v. - rectal/oral suspension - active: barium sulfate equivalent to 56% w/w.barium sulphate 99.0% w/v-101% w/v. excipient: citric acid monohydrate 0.1 - 0.2%w/v liquid orange flavour proprietary gums. 0.5%w/v -0.75% w/v maltol methyl hydroxybenzoate pectin potassium sorbate purified water saccharin sodium simeticone sorbitol

Australia - English - Department of Health (Therapeutic Goods Administration)

devlab consultants - barium sulfate, quantity: 12 mg/g - suspension - excipient ingredients: potassium sorbate; sodium benzoate; sucrose; citric acid; xanthan gum; sulfuric acid; purified water; bentonite; flavour - x-ray contrast agent

New Zealand - English - Medsafe (Medicines Safety Authority)

regional health ltd - barium sulfate 96.426%{relative};  ;   - powder for enema - 6.426% w/w - active: barium sulfate 96.426%{relative}     excipient: carrageenan pectin polyoxyethylene glyceryl mono-oleate simeticone sodium citrate dihydrate sorbitol tragacanth